D2V Clinical

Your milestones, Our mission At D2V Clinical, we accelerate drug development and collaborate with global biotech companies throughout the BLA/NDA approval. We assist companies in transforming innovative therapies into approved treatments. D2V Clinical, a full-service CRO, provides integrated regulatory strategy and agency interaction, medical strategy development, statistical analysis, SAS programming, Data Management, PK/PD analysis, and KOL interaction. Our team is proficient in dosing design with scientific justification, CMC review, and Toxicology/PV review to ensure efficient IND preparation and NDA submission. D2V Clinical provides expert consulting to help companies prepare, submit, and defend Investigational New Drug (IND) applications with the US FDA. We guide international companies through successful submissions to the FDA, EMA, PMDA, and NMPA. Our global team brings deep regulatory insight, enabling efficient, confident navigation of the complex regulatory landscape. With more than 20 years of leadership in clinical research, regulatory strategy, and investor value creation, D2V Clinical delivers the depth of knowledge you need to accelerate your program and avoid costly delays. We specialize in partnering with start-ups and early-stage biopharma companies, providing the strategic support and operational excellence required to bring your vision to life. Our track record includes: • Successful global marketing approval submissions • Proactive stakeholder engagement and risk mitigation • Predictive insights that keep your program on track Let D2V Clinical be your partner in transforming innovative therapies into impactful treatments — because your milestones are our missi